Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency while ensuring the safety of the funds and the implementation of investment projects [3][5][7]. Fundraising Overview - The company was approved to publicly issue 25 million shares at a price of RMB 40.29 per share, raising a total of RMB 100,725.00 million, with a net amount of RMB 90,975.85 million after deducting issuance costs [1][2]. - The funds are stored in a special account, and a tripartite supervision agreement has been signed with the sponsor and the commercial bank [2]. Investment Project Details - The total investment for the projects funded by the raised capital is RMB 65,000.48 million, with RMB 57,377.94 million planned from the raised funds and RMB 7,622.54 million from self-owned funds [2]. Cash Management Plan - The company intends to use up to RMB 52,600.00 million of temporarily idle funds for cash management within a 12-month period, ensuring it does not affect the implementation of investment projects [3][4][6]. - The investment products will include low-risk, high-liquidity options such as structured deposits, large-denomination certificates of deposit, and time deposits [4][5]. Impact on Operations - The cash management strategy is designed to improve fund efficiency without impacting the normal operations of the company or its investment projects, ultimately benefiting shareholders [5][7]. - The company aims to use the returns from cash management to supplement any shortfalls in project investments [4][5]. Approval Process - The board of directors and the supervisory board have approved the cash management plan, confirming compliance with relevant regulations and ensuring no adverse effects on the company's operations or shareholder interests [6][7][8].
麦澜德: 南京证券股份有限公司关于南京麦澜德医疗科技股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见